Nascent Biotech Inc. has engaged HRA Capital to help raise capital to fund the continual development of Pritumumab, a drug to treat brain cancer, through its phase 1 and phase 2 clinical trials.
HRA Capital to help raise funds for Nascent Biotech's brain cancer drug
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective
HRA Capital to help raise funds for Nascent Biotech's brain cancer drug
- Author Mirza Salam Ahmed
- Theme Healthcare & Pharmaceuticals
- Author
- Mirza Salam Ahmed
- Theme
- Healthcare & Pharmaceuticals